- Home
- RSI vs NAMS Comparison
RSI vs NAMS Comparison
Compare RSI & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RSI | NAMS |
|---|---|---|
| Founded | 2012 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | 100 |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.7B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | RSI | NAMS |
|---|---|---|
| Price | $31.32 | $29.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 8 |
| Target Price | $28.20 | ★ $46.75 |
| AVG Volume (30 Days) | ★ 2.4M | 961.2K |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 933.33 | N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $1,134,428,000.00 | N/A |
| Revenue This Year | $25.44 | $17.96 |
| Revenue Next Year | $14.27 | $540.65 |
| P/E Ratio | $391.50 | ★ N/A |
| Revenue Growth | ★ 22.76 | N/A |
| 52 Week Low | $15.18 | $21.14 |
| 52 Week High | $34.53 | $42.21 |
Technical Indicators
Market Signals| Indicator | RSI | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 49.12 | 41.00 |
| Support Level | $25.56 | $29.23 |
| Resistance Level | N/A | $37.29 |
| Average True Range (ATR) | 1.24 | 1.88 |
| MACD | -0.38 | -0.42 |
| Stochastic Oscillator | 17.08 | 8.00 |
Price Performance
Historical ComparisonAbout RSI Rush Street Interactive Inc.
Rush Street Interactive Inc is an online gaming and entertainment company that focuses on online casinos and online sports betting in the U.S. and Latin American markets. It provides customers with an array of gaming offerings such as real-money online casinos, online sports betting, and retail sports betting, as well as social gaming, which involves free-to-play games that use virtual credits that can be earned or purchased. The company generates revenue by offering online casinos, online sports betting, and social gaming directly to the end customer through its websites or apps. The company generates revenue through business-to-consumer (B2C) and business-to-business (B2B) models.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.